Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure

Cardiology Research and Practice

Volumn 1, Issue 1, 2013, Pages

  Komamura, Kazuo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PERINDOPRIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL;

CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIAGNOSTIC PROCEDURE; DIASTOLIC HEART FAILURE; DYSPNEA; EDEMA; HEART ATRIUM FIBRILLATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HUMAN; LUNG CONGESTION; MALAISE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOM; SYSTOLIC HEART FAILURE; TACHYCARDIA;

EID: 84896259390     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2013/824135     Document Type: Review

References (40)

1. Ouzounian M., Lee D. S., Liu P. P., Diastolic heart failure: mechanisms and controversies. Nature Clinical Practice Cardiovascular Medicine 2008 5 375 386 (Pubitemid 351935571)
2. Maeder M. T., Kaye D. M., Heart failure with normal left ventricular ejection fraction. Journal of the American College of Cardiology 2009 53 11 905 918 2-s2.0-61549090009 10.1016/j.jacc.2008.12.007
3. Borlaug B. A., Paulus W. J., Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal 2011 32 6 670 679 2-s2.0-79952829685 10.1093/eurheartj/ehq426
4. García E. H., Perna E. R., Farías E. F., Obregón R. O., Macin S. M., Parras J. I., Agüero M. A., Moratorio D. A., Pitzus A. E., Tassano E. A., Rodriguez L., Reduced systolic performance by tissue Doppler in patients with preserved and abnormal ejection fraction: new insights in chronic heart failure. International Journal of Cardiology 2006 108 2 181 188 2-s2.0-33644687894 10.1016/j.ijcard.2005.04.026 (Pubitemid 43330611)
5. Yip G., Wang M., Zhang Y., Fung J. W. H., Ho P. Y., Sanderson J. E., Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart 2002 87 2 121 125 2-s2.0-0036153340 (Pubitemid 34098370)
6. Skaluba S. J., Litwin S. E., Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation 2004 109 8 972 977 2-s2.0-1442285692 10.1161/01.CIR.0000117405.74491.D2 (Pubitemid 38282849)
7. Yamamoto K., Sakata Y., Ohtani T., Takeda Y., Mano T., Heart failure with preserved ejection fraction: what is known and unknown. Circulation Journal 2009 73 3 404 410 2-s2.0-62649167404 10.1253/circj.CJ-08-1073
8. Hunt S. A., Abraham W. T., Chin M. H., Feldman A. M., Francis G. S., Ganiats T. G., Jessup M., Konstam M. A., Mancini D. M., Michl K., Oates J. A., Rahko P. S., Silver M. A., Stevenson L. W., Yancy C. W., Antman E. M., Smith S. C. Jr., Adams C. D., Anderson J. L., Faxon D. P., Fuster V., Halperin J. L., Hiratzka L. F., Jacobs A. K., Nishimura R., Ornato J. P., Page R. L., Riegel B., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 112 12 e154 e235 2-s2.0-28744446343
9. Vasan R. S., Levy D., Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000 101 17 2118 2121 2-s2.0-0034595310 (Pubitemid 30233178)
10. Zile M. R., Gaasch W. H., Carroll J. D., Feldman M. D., Aurigemma G. P., Schaer G. L., Ghali J. K., Liebson P. R., Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001 104 7 779 782 2-s2.0-0035859889 (Pubitemid 32762675)
11. Zile M. R., Baicu C. F., Gaasch W. H., Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. The New England Journal of Medicine 2004 350 19 1953 1959 2-s2.0-3843094224 10.1056/NEJMoa032566 (Pubitemid 38580198)
12. Owan T. E., Hodge D. O., Herges R. M., Jacobsen S. J., Roger V. L., Redfield M. M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine 2006 355 3 251 259 2-s2.0-33746088001 10.1056/NEJMoa052256 (Pubitemid 44079340)
13. Bhatia R. S., Tu J. V., Lee D. S., Austin P. C., Fang J., Haouzi A., Gong Y., Liu P. P., Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine 2006 355 3 260 269 2-s2.0-33746033433 10.1056/NEJMoa051530 (Pubitemid 44088349)
14. Nagueh S. F., Appleton C. P., Gillebert T. C., Marino P. N., Oh J. K., Smiseth O. A., Waggoner A. D., Flachskampf F. A., Pellikka P. A., Evangelisa A., Recommendations for the evaluation of left ventricular diastolic function by echocardiography. European Journal of Echocardiography 2009 10 2 165 193 2-s2.0-62449330865 10.1093/ejechocard/jep007
15. van Veldhuisen D. J., Linssen G. C., Jaarsma T., B-type natriuretic Peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. Journal of the American College of Cardiology 2013 61 14 1498 1506
16. Brouwers F. P., de Boer R. A., van der Harst P., Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal 2013 34 1424 1431
17. Santhanakrishnan R., Chong J. P., Ng T. P., Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure 2012 14 1338 1347
18. van Kimmenade R. R. J., Januzzi J. L. Jr., Emerging biomarkers in heart failure. Clinical Chemistry 2012 58 1 127 138 2-s2.0-84856071476 10.1373/clinchem.2011.165720
19. Gaggin H. K., Januzzi J. L. Jr., Biomarkers and diagnostics in heart failure. Biochimica et Biophysica Acta 2013 10.1016/j.bbadis.2012.12.014
20. Cleland J. G. F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 27 19 2338 2345 2-s2.0-33748988737 10.1093/eurheartj/ehl250 (Pubitemid 44453578)
21. Yusuf S., Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J. V., Michelson E. L., Olofsson B., Östergren J., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 362 9386 777 781 2-s2.0-0041408234 10.1016/S0140-6736(03)14285-7 (Pubitemid 37093918)
22. Massie B. M., Carson P. E., McMurray J. J., Komajda M., McKelvie R., Zile M. R., Anderson S., Donovan M., Iverson E., Staiger C., Ptaszynska A., Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine 2008 359 23 2456 2467 2-s2.0-57349142933 10.1056/NEJMoa0805450
23. Hernandez A. F., Hammill B. G., O'Connor C. M., Schulman K. A., Curtis L. H., Fonarow G. C., Clinical effectiveness of beta-blockers in heart failure. Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry. Journal of the American College of Cardiology 2009 53 2 184 192 2-s2.0-58149097941 10.1016/j.jacc.2008.09.031
24. Fukuta H., Sane D. C., Brucks S., Little W. C., Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005 112 3 357 363 2-s2.0-22544443085 10.1161/CIRCULATIONAHA.104.519876 (Pubitemid 41022076)
25. Paulus W. J., van Ballegoij J. J. M., Treatment of heart failure with normal ejection fraction: an inconvenient truth! Journal of the American College of Cardiology 2010 55 6 526 537 2-s2.0-75249087216 10.1016/j.jacc.2009.06.067
26. Borlaug B. A., Melenovsky V., Marhin T., Fitzgerald P., Kass D. A., Sildenafil inhibits β -adrenergic-stimulated cardiac contractility in humans. Circulation 2005 112 17 2642 2649 2-s2.0-27444439573 10.1161/CIRCULATIONAHA.105.540500 (Pubitemid 41532601)
27. Vlachopoulos C., Hirata K., O'Rourke M. F., Effect of sildenafil on arterial stiffness and wave reflection. Vascular Medicine 2003 8 4 243 248 2-s2.0-2342587503 10.1191/1358863x03vm509ra (Pubitemid 38585138)
28. Katz S. D., Balidemaj K., Homma S., Wu H., Wang J., Maybaum S., Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. Journal of the American College of Cardiology 2000 36 3 845 851 2-s2.0-0033858827 10.1016/S0735-1097(00) 00790-7
29. Lewis G. D., Lachmann J., Camuso J., Lepore J. J., Shin J., Martinovic M. E., Systrom D. M., Bloch K. D., Semigran M. J., Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007 115 1 59 66 2-s2.0-33846099444 10.1161/CIRCULATIONAHA.106. 626226 (Pubitemid 46058612)
30. Chen H. H., Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! Journal of the American College of Cardiology 2007 49 10 1089 1091 2-s2.0-33847785230 10.1016/j.jacc.2006.12.013 (Pubitemid 46389361)
31. Redfield M. M., Lee K. L., Braunwald E., Evaluating the effectiveness of Sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study). NCT00763867, 2008, http://clinicaltrials.gov/
32. Daniel K. R., Wells G., Stewart K., Moore B., Kitzman D. W., Effect of aldosterone antagonism on exercise tolerance, doppler diastolic function, and quality of life in older women with diastolic heart failure. Congestive Heart Failure 2009 15 2 68 74 2-s2.0-65449189741 10.1111/j.1751-7133.2009.00056.x
33. Vaitkevicius P. V., Lane M., Spurgeon H., Ingram D. K., Roth G. S., Egan J. J., Vasan S., Wagle D. R., Ulrich P., Brines M., Wuerth J. P., Cerami A., Lakatta E. G., A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proceedings of the National Academy of Sciences of the United States of America 2001 98 3 1171 1175 2-s2.0-0035970120 10.1073/pnas.98.3.1171 (Pubitemid 32121205)
34. Kass D. A., Shapiro E. P., Kawaguchi M., Capriotti A. R., Scuteri A., DeGroof R. C., Lakatta E. G., Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001 104 13 1464 1470 2-s2.0-0035949502 (Pubitemid 32917336)
35. Little W. C., Zile M. R., Kitzman D. W., Hundley W. G., O'Brien T. X., Degroof R. C., The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. Journal of Cardiac Failure 2005 11 3 191 195 2-s2.0-16244371321 10.1016/j.cardfail.2004.09.010 (Pubitemid 40462421)
36. Borlaug B. A., Melenovsky V., Russell S. D., Kessler K., Pacak K., Becker L. C., Kass D. A., Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006 114 20 2138 2147 2-s2.0-33750995868 10.1161/CIRCULATIONAHA.106.632745 (Pubitemid 44747894)
37. Phan T. T., Abozguia K., Nallur Shivu G., Mahadevan G., Ahmed I., Williams L., Dwivedi G., Patel K., Steendijk P., Ashrafian H., Henning A., Frenneaux M., Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. Journal of the American College of Cardiology 2009 54 5 402 409 2-s2.0-67650547206 10.1016/j.jacc.2009.05.012
38. Kitzman D. W., Higginbotham M. B., Cobb F. R., Sheikh K. H., Sullivan M. J., Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. Journal of the American College of Cardiology 1991 17 5 1065 1072 2-s2.0-0025727274
39. Smith C. S., Bottomley P. A., Schulman S. P., Gerstenblith G., Weiss R. G., Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 2006 114 11 1151 1158 2-s2.0-33748668461 10.1161/CIRCULATIONAHA.106.613646 (Pubitemid 44386479)
40. Frenneaux M., Perhexiline therapy in heart failure with preserved ejection fraction syndrome. NCT00839228, 2009, http://clinicaltrials.gov/